Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Trending Stock Alerts

FLXN Stock - Flexion Therapeutics Stock Trading


home / stock / flxn

FLXN FLXN Quote FLXN Short FLXN News FLXN Articles FLXN Message Board

MWN AI Summary *

Flexion Therapeutics Inc. (NASDAQ: FLXN) is a biopharmaceutical company dedicated to developing and commercializing innovative pain management therapies that address unmet medical needs in patients suffering from osteoarthritis and other significant joint-related conditions. Founded in 2007 and headquartered in Burlington, Massachusetts, Flexion has emerged as a notable player in the pharmaceutical industry, particularly through its lead product, Zilretta (triamcinolone acetonide extended-release injectable suspension), which is designed for the intra-articular treatment of osteoarthritis knee pain.

Zilretta was granted FDA approval in October 2017 and represents a pivotal addition to pain management options for osteoarthritis due to its extended-release formulation that aims to provide sustained pain relief for patients. The company has cultivated a comprehensive commercialization strategy to launch Zilretta in the U.S. market, which includes establishing relationships with healthcare providers and payers to enhance access and adoption.

Despite challenges typical of the biopharmaceutical sector, including competition and market dynamics, Flexion has pursued a robust pipeline of product candidates. The company is committed to further expanding its offerings in the pain management space, including the exploration of new therapies and formulations. Additionally, Flexion continues to focus on leveraging its innovative drug delivery technology to optimize treatment efficacy while minimizing side effects.

As of October 2023, Flexion Therapeutics has been navigating the complexities of market competition, particularly amid the evolving landscape of non-opioid pain management solutions. Investors and analysts keep a close eye on the company’s financial performance, pipeline advancements, and strategic initiatives to gauge future growth potential. Overall, Flexion’s contributions to osteoarthritis treatment highlight its commitment to improving patient outcomes in a challenging therapeutic area.

MWN AI Analysis *

As of October 2023, investors considering Flexion Therapeutics Inc. (NASDAQ: FLXN) should carefully evaluate the company's potential amidst ongoing market dynamics in the biopharmaceutical sector. Flexion specializes in innovative treatments for patients with osteoarthritis and related conditions, which positions it favorably given the increasing prevalence of such diseases within an aging population.

Flexion's lead product, Zilretta, has shown promise as an extended-release injection for knee osteoarthritis. The drug's unique formulation enhances patient compliance and outcomes, but the company faces competitive pressures from a growing number of similar therapies entering the market. For investors, this highlights the importance of monitoring the company's marketing strategies and partnership developments, especially as broader trends in the healthcare sector evolve.

Financially, Flexion has undergone significant transformations, including restructuring efforts aimed at optimizing operations and reducing costs. A careful analysis of its cash flow statements and balance sheets reveals a critical need for sustainable revenue generation, particularly as research and development expenses remain high. Investors should be aware that ongoing clinical trials and any updates on new product candidates can dramatically influence stock performance.

On the macroeconomic front, fluctuations in healthcare regulations and reimbursement policies may also impact Flexion’s profitability. The recent trends toward value-based care could necessitate that Flexion demonstrates clear cost-effectiveness and improved patient outcomes to secure market access and adoption.

In conclusion, prospective investors should maintain a cautious but optimistic outlook on Flexion Therapeutics. Keeping an eye on the company’s strategic moves, clinical trial results, and industry trends will be key. Diversifying investments and preparing for volatility will also be prudent, given the inherent risks associated with biotech investments. Overall, Flexion presents a compelling opportunity but requires diligent monitoring to navigate its challenges and capitalize on potential successes.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Flexion Therapeutics Inc. (NASDAQ:FLXN)

Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra-articular corticosteroid treatment.

Quote | Flexion Therapeutics Inc. (NASDAQ:FLXN)

Last:$9.12
Change Percent: -0.22%
Open:$9.14
Close:$9.12
High:$9.225
Low:$9.12
Volume:18,722,853
Last Trade Date Time:11/18/2021 04:56:00 pm

News | Flexion Therapeutics Inc. (NASDAQ:FLXN)

  • Horizon Continues to Build Its Lineup of Exchange Traded Funds with the Launch of Two New Active Fixed Income ETFs

    Core Bond ETF (BNDY) and Flexible Income ETF (FLXN) expand the firm’s goals-based lineup, offering new tools for advisors to meet client objectives Horizon , a provider of highly customized investment and technology solutions designed to fuel the growth of financial advisor...

    • July 03, 2025 08:45:00 am

    • |
    • Business Wire
    • |
      • FLXN Stock
      • FLXN Quote
      • FLXN Short
      • FLXN News
      • FLXN Articles
      • FLXN Message Board

Message Board Posts | Flexion Therapeutics Inc. (NASDAQ:FLXN)

Subject By Source When
Let's go Brandon Docstemcell2020 investorshub 10/11/2021 12:53:56 PM
Just In: $FLXN Flexion Therapeutics Announces Preliminary Third-Quarter whytestocks investorshub 10/13/2020 7:30:25 PM
News: $FLXN Flexion Therapeutics Announces Preliminary Second-Quarter 202 whytestocks investorshub 07/14/2020 11:45:14 PM
News: $FLXN Flexion Therapeutics Announces Publication of Pooled whytestocks investorshub 05/10/2019 3:30:37 PM
News: $FLXN Flexion Therapeutics Names Christina Willwerth Chief whytestocks investorshub 01/22/2019 10:01:17 PM

MWN AI FAQ **

What are the latest developments in the product pipeline of Flexion Therapeutics Inc. (NASDAQ: FLXN), and how do they impact the company’s market position?

As of October 2023, Flexion Therapeutics Inc. is advancing its lead product, Zilretta, while exploring additional formulations and partnerships, which strengthen its competitive market position in pain management, but ongoing clinical results are crucial for future growth.

How has Flexion Therapeutics Inc. (NASDAQ: FLXN) performed financially over the past year, and what are its projections for revenue growth in the coming quarters?

Over the past year, Flexion Therapeutics Inc. (NASDAQ: FLXN) has faced financial challenges with fluctuating revenues, and while projections for future revenue growth indicate potential positive trends, uncertainty remains based on market conditions and product performance.

What strategic partnerships or collaborations has Flexion Therapeutics Inc. (NASDAQ: FLXN) established to enhance its research and development capabilities?

Flexion Therapeutics Inc. has established strategic partnerships with various organizations, including collaborations with academic institutions and industry players, to enhance its research and development capabilities, particularly in advancing treatments for pain management and osteoarthritis.

How does Flexion Therapeutics Inc. (NASDAQ: FLXN) plan to navigate the competitive landscape in the biotech sector, especially regarding its flagship products?

Flexion Therapeutics Inc. aims to navigate the competitive biotech landscape by focusing on strategic partnerships, enhancing its flagship product portfolio, and investing in R&D to address unmet medical needs while leveraging its unique clinical data for market differentiation.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get FLXN Alerts

News, Short Squeeze, Breakout and More Instantly...

Flexion Therapeutics Inc. Company Name:

FLXN Stock Symbol:

NASDAQ Market:

-0.22% G/L:

$9.12 Last:

18,722,853 Volume:

$9.14 Open:

$9.12 Close:

Flexion Therapeutics Inc. Website:

Flexion Therapeutics Inc. Logo

Ad

Trending Stock Alerts
RECENT FLXN NEWS
  • FLXN - Horizon Continues to Build Its Lineup of Exchange Traded Funds with the Launch of Two New Active Fixed Income ETFs

    Core Bond ETF (BNDY) and Flexible Income ETF (FLXN) expand the firm’s goals-based lineup, offering new tools for advisors to meet client objectives Horizon , a provider of highly customized investment and technology solutions designed to fuel the growth of financial advisor...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get FLXN Alerts

Get FLXN Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1